Prognostic Factors for Survival in Patients With Cholangiocarcinoma

Key facts

Sponsor

Rigshospitalet, Denmark

Principal Investigator

Hans-Christian Pommergaard, M.D./Ph.D.

Rigshospitalet, Denmark

Intervention

Resection/Ablation of tumor(procedure)

Enrollment

2000 enrolled

Eligibility

All sexes

Timeline

2024 – 2024

Study locations (1)

• Rigshospitalet, Copenhagen, Denmark

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07478523
  FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
  University Hospital, Bordeaux
• RECRUITINGNANCT07476651
  Scout Dose of Resin Microspheres
  Seoul National University Hospital
• RECRUITINGPHASE2NCT06728410
  A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
  Mehmet Akce
• RECRUITINGPHASE2NCT07201519
  Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
  Michael J Cavnar, MD
• RECRUITINGPHASE2NCT07223307
  REGULUS: MRI-guided Adaptive SABR for Liver Cancers
  Stanford University
• RECRUITINGPHASE2NCT07260175
  Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• RECRUITINGNANCT06735560
  Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN
  Nantes University Hospital
• RECRUITINGNCT07206355
  In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers
  University of Nottingham

See all trials for Cholangiocarcinoma →